Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Cloudia Research S.p.A. is a specialized company focused on biotechnology research and development, particularly within the medical and healthcare sectors. Its primary purpose is to advance scientific knowledge and create innovative solutions for pressing medical challenges, targeting diseases that require novel therapeutic approaches. The company is known for leveraging cloud-based technologies to enhance data analysis and streamline collaborative research efforts, making it a leader in using digital tools to accelerate biotechnological advancements. As such, Cloudia Research impacts industries including pharmaceuticals, diagnostics, and medical device manufacturing. By integrating cutting-edge technology with biological research, the company plays a significant role in advancing personalized medicine and improving patient outcomes. With a commitment to scientific rigor and innovation, Cloudia Research S.p.A. contributes to the broader life sciences market, pushing the boundaries of what is possible in healthcare and treatment solutions.
Operating margin is thin at 8.90%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 21.0%, still solid. Margins contracted 6.3pp, which offsets some of the top-line progress.
ROIC dropped from 24.26% to 10.61%, capital efficiency is deteriorating. Negative free cash flow of -€2M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€7M
▲ +21.0% YoY
Net Income (TTM)
€562K
▼ -13.1% YoY
Op. Margin
8.90%
▼ -6.3pp YoY
ROIC
10.61%
▼ -13.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€2M
▲ +10.8% YoY
Op. Cash Flow (TTM)
€131K
▲ +79.7% YoY
Net Debt
€333K
Cash & Equiv.
€1M
3Y CAGR: +49.1%
Continue Research